Floatz logo

Fingolimod

Rectal Neoplasms

Institut du Cancer de Montpellier - Val d'AurelleSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Rectal Neoplasms cohort.

Asset / SponsorPhaseRating
Eloxatin
Chongqing University Cancer Hospital
Phase 3BB
PROPOFOL
Uppsala University
Phase 4BB
Ertapenem
University of Ulm
Phase 4BB
FLUOROURACILUM
Pei-Rong Ding
Phase 3BB
Sevoflurane
Uppsala University
Phase 4BB

View all 44 →

Same molecule, other indications

Fingolimod is also rated in:

relapsing-remitting multiple sclerosisDormant
A
Indicative ·
82 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
70 / 100
View asset →
cerebral degenerationDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →